Mansoor Ashraf

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Antimicrobial Resistance

General Practice

Top Venues

JMIR public health and surveillance

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Uy Hoang, Gayathri Delanerolle, Xuejuan Fan, Carole Aspden, Rachel Byford, Mansoor Ashraf, Mendel D M Haag, William H Elson, Meredith Leston, Sneha N Anand, Filipa Ferreira, Mark P Joy, Frederick David Richard Hobbs, Simon de Lusignan
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort. JMIR public health and surveillance 10 (2024)
Uy Hoang, Gayathri Delanerolle, Xuejuan Fan, Carole Aspden, Rachel Byford, Mansoor Ashraf, Mendel D M Haag, William H Elson, Meredith Leston, Sneha N Anand, Filipa Ferreira, Mark P Joy, Frederick David Richard Hobbs, Simon de Lusignan
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort. JMIR public health and surveillance 10 (2024)
Uy Hoang, Gayathri Delanerolle, Xuejuan Fan, Carole Aspden, Rachel Byford, Mansoor Ashraf, Mendel D M Haag, William H Elson, Meredith Leston, Sneha N Anand, Filipa Ferreira, Mark P Joy, Frederick David Richard Hobbs, Simon de Lusignan
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort. JMIR public health and surveillance 10 (2024)
Uy Hoang, Gayathri Delanerolle, Xuejuan Fan, Carole Aspden, Rachel Byford, Mansoor Ashraf, Mendel D M Haag, William H Elson, Meredith Leston, Sneha N Anand, Filipa Ferreira, Mark P Joy, Frederick David Richard Hobbs, Simon de Lusignan
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort. JMIR public health and surveillance 10 (2024)
Mansoor Ashraf, Sankarasubramanian Rajaram, Peter M English
How the COVID 19 pandemic will shape influenza public health initiatives: The UK experience. Human vaccines & immunotherapeutics 18 (5) (2022)